- Price
- $13.14
- Day
- +0.77%
- Mkt Cap
- $453.61M
- 52W Range
- $8.12 – $13.74
- Volume
- 403.5K
- Beta
- 0.49
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver c.
Read full article
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, August 6, 202.
Read full article
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 17,000 s.
Read full article